Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

Genomics (NasdaqGS:TXG) is collaborating with PerturbAI, NVIDIA, and the Allen Institute on what is described as the largest in vivo CRISPR brain atlas. The partnership combines 10x Genomics' single ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

India has introduced national guidelines to ensure the safe and ethical use of CRISPR-based therapies, while stepping up efforts to build domestic capabilities in gene editing and advanced ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day.

CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...